For Patients & Caregivers

Helpful Resources for Your Practice

ENSPRYNG Access Solutions offers a range of access and reimbursement resources for your patients and practice after ENSPRYNG is prescribed, including help with benefits investigations (BIs), resources for prior authorizations (PAs), sample billing and coding information, resources for denials and appeals, information about distribution and referrals to potential financial assistance options.

Quick Links

Help with Coverage (BIs and PAs)
Reimbursement (Billing, Coding and Appeals)
Online Patient Enrollment
ENSPRYNG Distribution

Coverage

Get help understanding insurance benefits and coverage, such as with benefits investigations and prior authorization resources.

Benefits Investigations

ENSPRYNG Access Solutions can conduct a benefits investigation (BI) which can determine:

  • If treatment is covered
  • If treatment is denied
  • If a prior authorization or pre-determination is required*
  • If your patient's insurance plan has a mandated or preferred specialty pharmacy

*If your patient’s request for a prior authorization is not granted, your ENSPRYNG Access Solutions specialist can work with you to determine your next steps.

Get started with enrollment by following the steps below.

Option 1: Submit online

If your practice has a registered account for My Patient Solutions, you can get started by logging into your account.

Don't have an account?

Your patient is required to complete the patient consent section of the ENSPRYNG Start Form. You can either upload the patient consent section of the ENSPRYNG Start Form as part of your online application or have your patient submit the patient consent section of the ENSPRYNG Start Form via fax, text or e-submit.

  • An online tool to help you enroll patients in ENSPRYNG Access Solutions and manage your service requests at your convenience.

Option 2: Print & fax or text

Step 1: Print ENSPRYNG Start Form below and have your patient complete the patient consent section of this form.

Step 2: Submit the completed form via fax or text.

Both sections of the form are required. We must have both sections of the completed ENSPRYNG Start Form before we can help you.

What to expect next:

  • The request will be processed within five business days upon receipt of both patient and prescriber consent.
  • Your office will be contacted to discuss any next steps.

The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and healthcare provider. Genentech makes no representation or guarantee concerning coverage or reimbursement for any service or item.

ENSPRYNG Patient Navigators

A Patient Navigator may assist during your patient's treatment with access, reimbursement and injection training support.

Learn more about ENSPRYNG Patient Navigators

ENSPRYNG Benefits Reverification

When a medical treatment is authorized by the patient’s insurance plan for a limited period of time, it will generally require reverification of coverage for continued treatment. ENSPRYNG Access Solutions can help you obtain reverification for your patients.

If the patient’s health insurance plan denies the request for reverification, your practice may file an appeal on behalf of your patient.

Reimbursement

Sample coding information and resources for denials and appeals

ENSPRYNG Sample Coding

This coding information may assist you as you complete the payer forms for ENSPRYNG. These tables are provided for informational purposes only. Please visit CMS.gov or other payers’ websites to obtain additional guidance on their processes related to billing and coding.

Sample Coding: Thyroid Eye Disease (TED)

Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Appeals

If your patient’s health insurance plan has issued a denial, your ENSPRYNG Access Solutions specialist can provide resources as you prepare an appeal submission, as per your patient’s plan requirements. 

If a plan issues a denial: 

  1. The denial should be reviewed, along with the health insurance plan’s guidelines to determine what to include in your patient’s appeal submission.
  2. Your ENSPRYNG Access Solutions specialist has local payer coverage expertise and can help you determine specific requirements for your patient.

A sample appeal letter and additional considerations are available on the Practice Forms & Documents page.

Appeals cannot be completed or submitted by Genentech on your behalf.

Online Patient Enrollment

My Patient Solutions is an online tool to help you enroll patients in ENSPRYNG Access Solutions and manage your service requests, all through one portal. It allows you the flexibility to work with ENSPRYNG Access Solutions when it’s convenient for you.

With My Patient Solutions, you can:

  • Enroll and re-enroll patients in ENSPRYNG Access Solutions and/or the Genentech Patient Foundation
  • View Genentech Patient Foundation eligibility and coordinate shipment
  • Communicate with your ENSPRYNG Access Solutions specialist
  • Easily identify next steps for service requests
  • View Benefits Investigation reports for all your enrolled patients
  • Follow up on prior authorizations or appeals

How to register

Account registration can be completed by one person for the entire practice and for multiple practice locations. For help with registration or if you have questions, call us at 877-GENENTECH (877-436-3683) (6AM-5PM PST, Monday through Friday).

Register for My Patient Solutions

ENSPRYNG Distribution

Genentech has contracted with authorized specialty distributors and specialty pharmacies to service practices choosing to prescribe ENSPRYNG. 

These partners have made a commitment to product integrity and have agreed to distribute only products purchased directly from Genentech and not to distribute ENSPRYNG through secondary channels.

Authorized Distributors

For a full list of authorized distributors, please visit Genentech-Pro.com or contact ENSPRYNG Access Solutions at 844-677-7964.

About Buy and Bill

With Buy and Bill, the practice purchases the medication in advance, then bills the patient's health insurance plan for reimbursement. The practice is responsible for storing and handling the drug as well as collecting the patient's co-pay for both the drug and its administration. With Buy and Bill, practices can maintain a stock of the drug, giving them the flexibility to treat patients when clinically appropriate.

About Specialty Pharmacies

ENSPRYNG Access Solutions works with specialty pharmacies (SPs) to help patients receive their prescribed Genentech medicines.

In addition to distributing medicines, an SP may provide the following services:

  • Reimbursement resources
  • Clinical services to support patients throughout their treatment
  • The ability to manage the specialty handling and shipping needs linked with many specialty therapies

You can work with your preferred SP or contact ENSPRYNG Access Solutions to learn which SP the patient’s health insurance plan mandates or prefers.

For a full list of in-network specialty pharmacies, please visit Genentech-Pro.com or contact ENSPRYNG Access Solutions at 844-677-7964.

Genentech does not influence or advocate the use of any one specialty distributor or specialty pharmacy. We make no representation or guarantee of service or coverage of any item. For any product-specific distribution questions, call ENSPRYNG Access Solutions at 844-677-7964 (6AM-5PM PST, Monday through Friday).

Product Issues

We are serious about patient safety. If your Genentech product is spoiled, expired or damaged, we may be able to help you replace it.

Need more help? Click here to find the latest information.

Please contact Genentech Customer Service at 800-551-2231 for any order or return-related questions.

Contact Us

Need more help? Contact ENSPRYNG Access Solutions

Call 844-677-7964 (Mon.–Fri., 6AM–5PM PST).

Financial support

Financial Support

Find the right financial resources option for your patients.

Explore options
NEXT: Practice Forms & Documents

  • We are open from 6AM-5PM PST, Mon. through Fri., except for the following holidays:

    • New Year’s Day
    • Martin Luther King, Jr. Day
    • Memorial Day
    • Juneteenth
    • Independence Day
    • Labor Day
    • Thanksgiving Holiday (Thursday and Friday)
    • Christmas Day

Important Safety Information & Indication

Indication

ENSPRYNG® (satralizumab-mwge)  is indicated for the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients.

Contraindications

ENSPRYNG is contraindicated in patients with a known hypersensitivity to satralizumab or any of the inactive ingredients, an active hepatitis B infection, or active or untreated latent tuberculosis.

Warnings and Precautions

Infections
An increased risk of infections, including serious and potentially fatal infections, has been observed in patients treated with IL-6 receptor antagonists, including ENSPRYNG. The most common infections reported in a randomized clinical trial of patients treated with ENSPRYNG who were not on other chronic immunosuppressant therapies, and that occurred more often than in patients receiving placebo, were nasopharyngitis (12%) and cellulitis (10%). The most common infections in patients who were on an additional concurrent immunosuppressant, and that occurred more often than in patients receiving placebo, were nasopharyngitis (31%), upper respiratory infection (19%), and pharyngitis (12%). Delay ENSPRYNG administration in patients with an active infection, including localized infections, until the infection is resolved.

Hepatitis B Virus (HBV) Reactivation
Risk of HBV reactivation has been observed with other immunosuppressant therapies. Patients with chronic HBV infection were excluded from clinical trials. Perform HBV screening in all patients before initiation of treatment with ENSPRYNG. Do not administer ENSPRYNG to patients with active hepatitis. For patients who are chronic carriers of HBV [HBsAg+] or are negative for HBsAg and positive for HB core antibody [HBcAb+], consult liver disease experts before starting and during treatment with ENSPRYNG.

Tuberculosis
Tuberculosis has occurred in patients treated with other IL-6 receptor antagonists. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating ENSPRYNG. Consider anti-tuberculosis therapy prior to initiation of ENSPRYNG in patients with a history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consult infectious disease experts regarding whether initiating anti-tuberculosis therapy is appropriate before starting treatment. Patients should be monitored for the development of signs and symptoms of tuberculosis with ENSPRYNG, even if initial tuberculosis testing is negative.

Vaccinations
Live or live-attenuated vaccines should not be given concurrently with ENSPRYNG because clinical safety has not been established. Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ENSPRYNG for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ENSPRYNG for non-live vaccines.

Elevated Liver Enzymes
Mild and moderate elevations of liver enzymes have been observed in patients treated with ENSPRYNG at a higher incidence than in patients receiving placebo. ALT and AST levels should be monitored every 4 weeks for the first 3 months of treatment, followed by every 3 months for one year, and thereafter, as clinically indicated.

Decreased Neutrophil Counts
Decreases in neutrophil counts were observed in patients treated with ENSPRYNG at a higher incidence than placebo. Neutrophil counts should be monitored 4 to 8 weeks after initiation of therapy, and thereafter at regular clinically determined intervals.

Hypersensitivity Reactions
Hypersensitivity reactions, including rash, urticaria, and fatal anaphylaxis, have occurred with other IL-6 receptor antagonists.


Use in Specific Populations

Pregnancy
There are no adequate data on the developmental risk associated with the use of ENSPRYNG in pregnant women. In an animal reproduction study, no adverse effects on maternal animals or fetal development were observed in pregnant monkeys and their offspring, with administration of ENSPRYNG at doses up to 50 mg/kg/week. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2 – 4% and 15 – 20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. ENSPRYNG should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation
No information is available on the presence of ENSPRYNG in human milk, the effects of ENSPRYNG on the breastfed infant, or the effects of ENSPRYNG on milk production. ENSPRYNG was excreted in the milk of lactating monkeys administered ENSPRYNG throughout pregnancy. Human IgG is excreted in human milk and the potential for absorption in the infant is unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ENSPRYNG and any potential adverse effects on the breastfed infant from ENSPRYNG or from the underlying maternal condition.

Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

Geriatric Use
Clinical studies of ENSPRYNG did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. However, population pharmacokinetic analyses in patients with NMOSD did not show that age affected the pharmacokinetics of ENSPRYNG. In general, caution should be used when dosing the elderly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.

Most Common Adverse Reactions
The most common adverse reactions in patients with TED (incidence ≥5% and greater than placebo) were upper respiratory tract infection (5%), and alanine aminotransferase increased (5%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional safety information, please see the full Prescribing Information and Medication Guide.

    • ENSPRYNG [package insert]. South San Francisco, CA: Genentech, Inc; 2026.

      ENSPRYNG [package insert]. South San Francisco, CA: Genentech, Inc; 2026.

    • Subramanian P, et al. Presented at North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting. March 20-24, 2026.

      Subramanian P, et al. Presented at North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting. March 20-24, 2026.

    • Bennett JL, et al. Neurol Neuroimmunol Neuroinflamm. 2025;12(5):e200450.

      Bennett JL, et al. Neurol Neuroimmunol Neuroinflamm. 2025;12(5):e200450.

    • Murdock J, et al. Front. Ophthalmol. 2025; 5:1544436.

      Murdock J, et al. Front. Ophthalmol. 2025; 5:1544436.

    • Ezra DG, et al. Rev Endocr Metab Disord. 2026; 27(2):237-253.

      Ezra DG, et al. Rev Endocr Metab Disord. 2026; 27(2):237-253.

    • Ezra DG, et al. Ophthalmol Ther. 2025; 14(12):3119-3132.

      Ezra DG, et al. Ophthalmol Ther. 2025; 14(12):3119-3132.

    TOP
    +